Business Wire

Boku Connects Poland’s 16.3m BLIK Users Into Google With New Payment Relationship

Share

Boku Inc. (LON: BOKU), the global network for localized payment solutions, is pleased to announce that it now supports BLIK, the instant payment system in Poland, as a payment method for Google Play Store. With this launch, BLIK’s 16.3 million active users will be able to use their preferred payment method when making purchases from the Google Play Store.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604616574/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boku connects Poland’s 16.3m BLIK users into Google with new payment relationship (Graphic: Business Wire)

BLIK is Boku’s first account to account (A2A) connection with Google, extending the strong relationship that the global payments network already has with Google through Boku’s Direct Carrier Billing solution. Offering BLIK as a payment option will enable Google to not only grow its current user base on the Google Play Store, but further enhance customer satisfaction and loyalty amongst Poland’s mobile-first consumers who want quicker and more convenient payment choices.

BLIK is a key payment system in Poland offering a fast, secure and convenient way of payment where users do not have to give their data to fulfil a payment. Last year, The National Bank of Poland classified BLIK as one of the "significant retail payment systems" in the Polish market, and it is now the most frequently used payment method for online purchases in the country with half of the adult population using its services.

BLIK is gaining popularity, as evidenced by both consistently growing transactional results and the number of active users, which reached 16.3 million in the first quarter of 2024. In the first three months of 2024, users completed 518 million transactions, of which 264.9 million were in online stores. This represents a 28 percent increase of e-commerce payments compared to the same period in 2023.

Stuart Neal, Boku’s CEO, commented: “We are very pleased to see BLIK go live as a payment option for Google Play Store in Poland. This is our first A2A connection with Google, a company we have had a relationship with for several years, providing them with Direct Carrier Billing solutions. Our mission at Boku is to empower people everywhere to pay for the services they love the way they want, and allow global merchants to seamlessly offer localized payment choice in order to unlock new growth around the world. With local payment methods continuing to grow in popularity, we’re excited to be part of Google’s future payment innovation.”

Magdalena Kubisa, Director Of Business Development at BLIK, commented: “BLIK is a versatile payment method that is already the top choice for online purchase for many Poles. Therefore, we are delighted to expand our network of availability, and through collaboration with Boku, BLIK will be one of the available payment methods for Google Play. For us, this is another strategic step in the development and growth of our system.”

About Boku Inc.

Boku helps people pay the way they want to by building a global network of localized payment solutions including digital wallets, direct carrier billing, and account to account / real-time payments schemes. Boku’s global payments network now includes over 300 local payment methods worldwide, reaching over 7.5 billion consumer payment accounts in more than 90 countries. Boku works with the world’s largest merchants including Amazon, Google, Spotify, Meta, Microsoft, Netflix, Spotify, Tencent and Sky, helping them to grow their businesses in every corner of the globe.

Boku Inc. was incorporated in 2008 and is headquartered in London, UK, with offices in the US, India, Brazil, China, Estonia, France, Germany, Indonesia, Japan, Singapore, Spain, Taiwan and Vietnam.

To learn more about Boku, please visit our website at www.boku.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cat Lenheim
ThoughtLDR
cat@thoughtldr.com
+44 7511 117587

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions21.6.2024 21:45:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye